Daniel Muñoz-Pichuante

Daniel Muñoz-Pichuante

Auto-generated profile, based on publicly available information

Daniel Muñoz-Pichuante

Escuela de Química y Farmacia, Facultad de Ciencias Universidad San Sebastián Valdivia Chile

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 June 2020 in Journal of Clinical Pharmacy and Therapeutics
Verified
Journal Article
Closed access
PDF file
DMDaniel Muñoz‐Pichuante
Daniel Muñoz‐Pichuante
LZLORENZO VILLA ZAPATA
LORENZO VILLA ZAPATA

23 July 2023 in JACCP: Journal of the American College of Clinical Pharmacy
Verified
Journal Article
Closed access
KCKevin José Cruz-Mora
Kevin José Cruz-Mora
BSBruno Serrano‐Arias
Bruno Serrano‐Arias
AMAntonella Milano‐Gil
Antonella Milano‐Gil
CSCesar Sanchez‐Solis
Cesar Sanchez‐Solis
DADadier Antonio Arroyo‐Monterrosa
Dadier Antonio Arroyo‐Monterrosa
Jose Miguel Chaverri-FernandezJose Miguel Chaverri-Fernandez
Jose Miguel Chaverri-Fernandez

1 June 2020 in Drug Metabolism and Drug Interactions
Verified
Journal Article
Closed access
PDF file
DMDaniel Muñoz-Pichuante
Daniel Muñoz-Pichuante
LZLORENZO VILLA ZAPATA
LORENZO VILLA ZAPATA
RLRussi Lolas
Russi Lolas
Objectives: Valproic acid (VPA) is an anticonvulsant used in several clinical scenarios. VPA has been increasingly associated with intentional or unintentional overdose. In patients presenting with severe VPA overdose, supportive care and airway protection are cornerstones of treatment, while levocarnitine is suggested in patients with hyperammonemia and hemodialysis is recommended in patients with VPA serum concentrations (SC) >1,300 mg/L and presence of cerebral edema or shock. Meropenem is a carbapenem antibiotic with a broad spectrum of activity. The pharmacological interaction between VPA and meropenem is characterized by a rapid decrease in VPA concentrations, which contraindicates concurrent use. Case presentation: The following case report describes the use of meropenem to enhance the clearance of VPA in the case of severe VPA overdose. A patient with altered mental status was transported to the emergency department (ED) after VPA overdose. Meropenem was prescribed for significant elevated VPA SC. An important decline in SC was observed with short-term meropenem dosing, and an improvement in mental status occurred shortly after administration. Conclusions: Carbapenem therapy has the potential to be used as last line strategy in the management of severe VPA overdose in patients where SC represent a significant risk of toxicity and clinical symptoms suggest difficulty managing the patient.

16 June 2020 in medRxiv
Verified
Preprint
Open access
PDF file
FOFelipe Olivares
Felipe Olivares
DMDaniel Muñoz
Daniel Muñoz
AFAlberto Fica
Alberto Fica
IDIgnacio Delama
Ignacio Delama
IAIgnacia Alvarez
Ignacia Alvarez
JGJuan Grandjean
Juan Grandjean
During the first pandemic wave Covid-19 reached Latin America cities. Aim: To report clinical features and outcomes associated to Covid-19 in a group of patients admitted during the first wave in a regional reference Center in southern Chile designated to severe and critical cases. Methods: Cases were identified by a compatible clinical picture associated to positive RT-PCR or serological testing. A standard protocol was applied. Results: 21 adult patients (20 diagnosed by PCR, one by serology) were admitted between epidemiological weeks 13 to 20, involving 8.8% of total regional cases. Hospitalization occurred at a median of 11 days after symptoms onset. Patients ≥60 years old predominated (57.1%). Hypertension (61.9%), obesity (57.1%) and diabetes mellitus 2 (38.1%) were prevalent but 19% had no comorbid conditions nor were elderly. Two cases involved second-trimester pregnant women. Positive IgM or IgM/IgG results obtained by rapid serological testing were limited (19% at 1st week; 42.9% at 2nd week). Nine patients (42.9%, critical group) were transferred to ICU and connected to mechanical ventilation due to respiratory failure. By univariate analysis admission to ICU was significantly associated to tachypnea and higher plasmatic LDH values. One pregnant woman required urgent cesarean section given birth to a premature neonate without vertical transmission. Two patients died (in-hospital mortality 9.5%) and length of stay was ≥ 14 days in 57.9% of patients. Conclusion: In our regional Center, Covid 19 was associated to known risk factors, had a prolonged stay and in-hospital mortality. Tachypnea ≥30/min is predictive of transfer to ICU.

4 March 2026 in Journal of Antimicrobial Chemotherapy
Verified
Journal Article
Closed access
DMDaniel Muñoz-Pichuante
Daniel Muñoz-Pichuante
JSJaime Sasso
Jaime Sasso
Ricardo Nalda-MolinaRicardo Nalda-Molina
Ricardo Nalda-Molina
ARAmelia Ramon-Lopez
Amelia Ramon-Lopez
LVLorenzo Villa-Zapata
Lorenzo Villa-Zapata
Continuous infusion (CI) of linezolid has been proposed to stabilize exposure and improve pharmacokinetic/pharmacodynamic (PK/PD) target attainment compared with conventional intermittent dosing. By maintaining concentrations above inhibitory thresholds, CI may optimize antibacterial efficacy and reduce inter- and intra-patient variability. However, this ‘new way of dosing’ revisits ‘old risks’ associated with linezolid, including nonlinear PK, metabolic saturation, and concentration-dependent toxicities such as lactic acidosis, myelosuppression and neurotoxicity. Rather than eliminating these concerns, CI may accentuate them by prolonging exposure near toxic thresholds, particularly in patients with impaired elimination. Current evidence is predominantly PK; robust clinical outcome data remain limited. Our review synthesizes pharmacometric, observational and trial data and outlines how therapeutic drug monitoring and model-informed precision dosing can be used to individualize CI while surveilling for toxicity. We propose a pragmatic framework for candidate selection, regimen design aligned to PK/PD goals, early therapeutic drug monitoring with adaptive adjustments and vigilant safety monitoring. Overall, CI of linezolid is mechanistically attractive but is not established as standard of care; its use should remain individualized, safety-conscious and evidence-generating pending randomized controlled trials.

18 December 2019 in Drug Metabolism and Personalized Therapy
Verified
Journal Article
Closed access
PDF file
DMDaniel Muñoz-Pichuante
Daniel Muñoz-Pichuante
LZLorenzo Villa Zapata
Lorenzo Villa Zapata
SCSalvador Cabrera
Salvador Cabrera
XLXimena Lagos
Ximena Lagos
JGJuan Grandjean
Juan Grandjean
Phenytoin is widely used in neurocritical patients. Owing to its high pharmacokinetic variability and narrow therapeutic range, plasma level-guided dosing has become the standard. Bayesian prediction (BP) is considered the most flexible and precise pharmacokinetic strategy among several options. A retrospective study of BP dosage adjustment in 20 patients (35 plasma measures) was developed. Results indicated that 70% of phenytoin plasma levels of first plasma samples were beyond the therapeutic range. Phenytoin doses were also estimated according to BP for all patients. The measurements confirmed the ability of the strategy to lead to optimal dosage in 80% of patients, thus indicating a three-fold improvement over the basing dosage adjustment recommended in the literature.